Comparing the prognosis of esophageal adenocarcinoma with bone and liver metastases: A competing risk analysis
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0303842 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Xinglian Zhu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory, Panyu Hexian Memorial Hospital of Guangzhou, China. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Adenocarcinoma, Liver Neoplasms, Bone Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Key Research and Development Program of China.
Abstract (Originalsprache)
Background
About half of the patients with esophageal cancer are presenting with metastasis at initial diagnosis. However, few studies have concerned on the prognostic factors of metastatic esophageal adenocarcinoma (mEAC). This research aimed to investigate the effects of single bone metastasis (BM) and single liver metastasis (LM) on prognosis of mEAC patients.
Methods
Data were obtained from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program database. We compared the effects of LM and BM on overall survival (OS), EAC-specific survival (CSS), and EAC-specific death (EASD) by multivariate Cox regression, Kaplan-Meier analysis, and competing risk regression models.
Results
A total of 1,278 EAC patients were recruited in this study. Of which 78.95% (1009/1278) were EASD, and 12.68% (162/1278) were non-EAC-specific death (non-EASD). In multivariate Cox regression analysis, surgery, chemotherapy, and AJCC.T2 ( vs . T1) were identified as protective factors for OS&CSS, while divorced/separated, single/unmarried ( vs . married), grade III-IV ( vs . grade I-II) and BM ( vs . LM) were identified as risk factors. Competing risk regression analysis further confirmed that surgery and chemotherapy were beneficial to the patients with mEAC, and BM ( vs . LM) was a risk factor for mEAC patients when considering the existence of the competitive risk events.
Conclusion
Our study indicated that mEAC patients with BM face a worse prognosis compared to those with LM. Additionally, surgery and chemotherapy emerge as protective factors for mEAC patients. These findings offer evidence-based insights for clinical management and contribute to the field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Respiratory, Panyu Hexian Memorial Hospital of Guangzhou, China.
- The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
- Guangdong Provincial Key Laboratory of Infectious Diseases and Molecular Immunopathology, Institute of Oncologic Pathology, Cancer Research Center, Shantou University Medical College, Shantou, China.
- Department of Neurology, Shenzhen People's Hospital, Shenzhen, China.
- Food Inspection and Quarantine Technology Center of Shenzhen Customs District, Shenzhen, China.
ORCID-Profile: Fang Zhao
Förderung
- the National Key Research and Development Program of China
Zitieren
APA
Zhu, X., Mo, M., Zheng, S., Han, K., Li, G., & Zhao, F. (2024). Comparing the prognosis of esophageal adenocarcinoma with bone and liver metastases: A competing risk analysis. PLOS ONE. https://doi.org/10.1371/journal.pone.0303842
Vancouver
Zhu X, Mo M, Zheng S, Han K, Li G, Zhao F. Comparing the prognosis of esophageal adenocarcinoma with bone and liver metastases: A competing risk analysis. PLOS ONE. 2024. doi:10.1371/journal.pone.0303842
BibTeX
@article{Zhu2024,
author = {Zhu, Xinglian and Mo, Mingxing and Zheng, Shaojun and Han, Kunning and Li, Guoyang and Zhao, Fang},
title = {Comparing the prognosis of esophageal adenocarcinoma with bone and liver metastases: A competing risk analysis},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0303842}
}
EUVIMED